Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer

Treatment with EGFR kinase inhibitors improves progression-free survival of patients with EGFR-mutant lung cancer. However, all patients with initial response will eventually acquire resistance and die from tumor recurrence. We found that intermittent high-dose treatment with erlotinib induced apopt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Schöttle, Jakob, Chatterjee, Sampurna, Volz, Caroline, Siobal, Maike, Florin, Alexandra, Rokitta, Dennis, Hinze, Yvonne, Dietlein, Felix, Plenker, Dennis, König, Katharina, Albus, Kerstin, Heuckmann, Johannes M., Rauh, Daniel, Franz, Thomas, Neumaier, Bernd, Fuhr, Uwe, Heukamp, Lukas C., Ullrich, Roland T.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4770714/
https://ncbi.nlm.nih.gov/pubmed/26540572
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados